Find A Doctor Find A Service Make An Appointment Talk To A Doctor

McDowell Cancer Centerbanner
increase text size decrease text size printer friendly



> Centers & Services > Cancer Institute
 

Cancer Clinical Trials

Akron General's McDowell Cancer Institute provides patients with access to care quickly. We also offer the newest therapies, diagnostics and surgical techniques to help minimize side effects and improve outcomes. A research site with national clinical trials, we offer treatment options that may help extend and improve lives. The McDowell Cancer Institute is a main member of NRG Oncology. NGR Oncology is a non-profit research organization formed to conduct oncologic clinical research and is funded by the National Cancer Institute (NCI). The McDowell Cancer Institute also has access to the Cancer Trails Support Unit (CTSU) menu of clinical trials. The CTSU is also a service of the NCI designed to facilitate access to NCI-funded clinical trials. We also participate in pharmaceutical and in-house investigator-initiated studies.  

Read more from Akron General:
What is a Clinical Trial?
View all Akron General Clinical Trials

For more information about options available through our cancer center clinical trials, please contact the McDowell Cancer Institute Research Department at 330.344.6348.

See below for active trials at the Akron General McDowell Cancer Institute.


Additional Resources for Cancer Clinical Trials:

National Institutes of Health, National Cancer Institute
www.nci.nih.gov

American Cancer Society
www.cancer.org

 Date Updated: 18-APR-2016
  
Brain Cancer
Breast Cancer
Cervical Cancer
Colon Cancer
Gastrointestinal
Gynecology
Head and Neck Cancer
Leukemia
Liver Cancer
Lung Cancer
Lung Cancer
Lymphoma
Metastatic Cancer
Pancreas Cancer
Prostate Cancer

Cancer Clinical Trials

Bone and Spine Cancer

Title(s):
RTOG 0631. Phase II/III Study of Image-Guided Radiosurgery/SBRT for Localized Spine Metastasis

Investigator(s):
Mitchel Fromm, MD

Contact Information:
McDowell Cancer Research at 330-344-6348


Go to top

Brain Cancer

Title(s):
NRG-BN001. Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation With Concomitant and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma

Investigator(s):
Mitchel Fromm, MD

Contact Information:
McDowell Cancer Research at 330-344-6348


Go to top

Brain Cancer

Title(s):
CTSU A071102. A Phase II/III Randomized Trial Of Veliparib Or Placebo In Combination With Adjuvant Temozolomide In Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

Investigator(s):
Esther Rehmus, MD

Contact Information:
McDowell Cancer Research at 330-344-6348


Go to top

Brain Cancer

Title(s):
CTSU A221101. A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (NuvigilĀ®) to Reduce Cancer-Related Fatigue in Patients with High Grade Glioma

Investigator(s):
Esther Rehmus, MD

Contact Information:
McDowell Cancer Research at 330-344-6348


Go to top

Brain Cancer

Title(s):
NRG-CC001. A Randomized, Phase III Trial Of Memantine and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Patients With Brain Metastases

Investigator(s):
Mitchel Fromm, MD

Contact Information:
McDowell Cancer Research at 330-344-6348


Go to top

Brain Cancer

Title(s):
NRG-CC003. Randomized phase II/III trial of prophylactic cranial irradiation with or without hippocampal avoidance for small cell lung cancer

Investigator(s):
Mitchel Fromm, MD

Contact Information:
McDowell Cancer Research at 33-344-6348


Go to top

Brain Cancer

Title(s):
CTSU A221208. Randomized Phase II Study: Corticosteroids + Bevacizumab Vs. Corticosteroids + Placebo (Best) For Radionecrosis After Radiosurgery For Brain Metastases

Investigator(s):
Esther Rehmus, MD

Contact Information:
McDowell Cancer Research at 330-344-6348


Go to top

Breast Cancer

Title(s):
SWOG 1207. Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer

Investigator(s):
Esther Rehmus, MD

Contact Information:
McDowell Cancer Research at 330-344-6348


Go to top

Breast Cancer

Title(s):
NSABP B-51/RTOG 1304. A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chest Wall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy

Investigator(s):
Andrew Fenton, MD

Contact Information:
McDowell Cancer Research at 330-344-6348


Go to top

Breast Cancer

Title(s):
CTSU E2112. A Randomized Phase III Trial of Endocrine Therapy plus Entinostat/Placebo in Postmenopausal Patients with Hormone Receptor-Positive Advanced Breast Cancer

Investigator(s):
Esther Rehmus, MD

Contact Information:
McDowell Cancer Research at 330-344-6348


Go to top

Breast Cancer

Title(s):
NSABP B-55/BIG 6-13. A Randomised, Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy

Investigator(s):
Andrew Fenton, MD

Contact Information:
McDowell Cancer Research at 330-344-6348


Go to top

Breast Cancer

Title(s):
CTSU A011202. A Randomized Phase III Trial Evaluating the Role of Axillary Lymph Node Dissection in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy

Investigator(s):
Esther Rehmus, MD

Contact Information:
McDowell Cancer Research at 330-344-6348


Go to top

Breast Cancer

Title(s):
CTSU EA1131. A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy

Investigator(s):
Esther Rehmus, MD

Contact Information:
McDowell Cancer Research at 330-344-6348


Go to top

Breast Cancer

Title(s):
NRG-BR003. A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer

Investigator(s):
Esther Rehmus, MD

Contact Information:
McDowell Cancer Research at 330-344-6348


Go to top

Breast Cancer

Title(s):
CTSU A011203. A Randomized Phase II Trial of Tamoxifen Versus Z-Endoxifen HCl in Postmenopausal Women with Metastatic, Estrogen Receptor Positive, HER2 Negative Breast Cancer

Investigator(s):
Esther Rehmus, MD

Contact Information:
McDowell Cancer Research at 330-344-6348


Go to top

Breast Cancer

Title(s):
NRG-BR002. A Phase IIR/III Trial of Standard of Care with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer

Investigator(s):
Mitchell Fromm, MD

Contact Information:
McDowell Cancer Research at 330-344-6348


Go to top

Breast Cancer

Title(s):
NRG-BR001. A Phase 1 Study of Stereotactic Body Radiotherapy (SBRT) for the Treatment of Multiple Metastases

Investigator(s):
Mitchel Fromm, MD

Contact Information:
McDowell Cancer Research at 330-344-6348


Go to top

Breast Cancer

Title(s):
15045. Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry (IMPACt)

Investigator(s):
Esther Rehmus, MD

Contact Information:
McDowell Cancer Research at 330-344-6348


Go to top

Breast Cancer

Title(s):
15043. Nipple Sparing Mastectomy Registry

Investigator(s):
Mary Murray, MD

Contact Information:
McDowell Cancer Research at 330-344-6348


Go to top

Breast Cancer

Title(s):
CTSU A011104 / 6694. Effect of Preoperative Breast MRI on Surgical Outcomes, Costs and Quality of Life of Women with Breast Cancer

Investigator(s):
Esther Rehmus, MD

Contact Information:


Go to top

Breast Cancer

Title(s):
CTSU A221102. Randomized Double-Blind Placebo Controlled Study Of Testosterone In The Adjuvant Treatment Of Postmenopausal Women With Aromatase Inhibitor Induced Arthralgias

Investigator(s):
Esther Rehmus, MD

Contact Information:
McDowell Cancer Research at 330-344-6348


Go to top

Breast Cancer

Title(s):
CTSU A011401. Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer

Investigator(s):
Esther Rehmus, MD

Contact Information:
McDowell Cancer Research at 330-344-6348


Go to top

Cervical Cancer

Title(s):
RTOG/GOG 0724. Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical Hysterectomy

Investigator(s):
Mitchel Fromm, MD

Contact Information:
McDowell Cancer Research at 330-344-6348


Go to top

Colon Cancer

Title(s):
13026. Ohio Colorectal Cancer Prevention Initiative: Universal Screening for Lynch Syndrome

Investigator(s):
Scott McGee, MD

Contact Information:
McDowell Cancer Research at 330-344-6348


Go to top

Gastrointestinal

Title(s):
CTSU A091401. Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Patient with Metastatic or Unresectable Sarcoma

Investigator(s):
Esther Rehmus, MD

Contact Information:
McDowell Cancer Research at 330-344-6348


Go to top

Gynecology

Title(s):
NRG-GY003. Phase II Randomized Trial of Nivolumab with or without Ipilimumab in Patients with Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer

Investigator(s):
Esther Rehmus, MD

Contact Information:
McDowell Cancer Research at 330-344-6348


Go to top

Gynecology

Title(s):
NRG-GY004. A Phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in women with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer

Investigator(s):
Esther Rehmus, MD

Contact Information:
McDowell Cancer Research at 330-344-6348


Go to top

Gynecology

Title(s):
NRG-GY005. A Randomized Phase II/III study of the combination of Cediranib and Olaparib compared to Cediranib or Olaparib alone, or Standard of care chemotherapy in women with recurrent platinum-resistant or -refractory ovarian, fallopian tube, or primary peritoneal cancer (COCOS)

Investigator(s):
Esther Rehmus, MD

Contact Information:
McDowell Cancer Research at 330-344-6348


Go to top

Head and Neck Cancer

Title(s):
RTOG 1216. Randomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered with Concurrent Cisplatin versus Docetaxel versus Docetaxel and Cetuximab for High-Risk Squamous Cell Cancer of the Head and Neck

Investigator(s):
Mitchel Fromm, MD

Contact Information:
McDowell Cancer Research at 330-344-6348


Go to top

Head and Neck Cancer

Title(s):
NRG-HN001. Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)

Investigator(s):
Mitchel Fromm, MD

Contact Information:
McDowell Cancer Research at 330-344-6348


Go to top

Leukemia

Title(s):
16004. Case No. 5Z08 Clinical Trial Center for Hematologic Malignancies, The Leukemia & Lymphoma Society and Cleveland Clinic Taussig Cancer Center Partnership Tissue Acquisition

Investigator(s):
Esther Rehmus, MD

Contact Information:
McDowell Cancer Research at 330-344-6348


Go to top

Leukemia

Title(s):
NHLBI-MDS. The National Myelodysplastic Syndromes (MDS) Study

Investigator(s):
Esther Rehmus, MD

Contact Information:
McDowell Cancer Research at 330-344-6348


Go to top

Liver Cancer

Title(s):
RTOG 1112. Randomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma

Investigator(s):
Mitchel Fromm, MD

Contact Information:
McDowell Cancer Research at 330-344-6348


Go to top

Lung Cancer

Title(s):
EA5142. Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers

Investigator(s):
Esther Rehmus, MD

Contact Information:
McDowell Cancer Research at 330-344-6348


Go to top

Lung Cancer

Title(s):
CTSU CALGB 30610. Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer also Receiving Cisplatin and Etoposide

Investigator(s):
Esther Rehmus, MD

Contact Information:
McDowell Cancer Research at 330-344-6348


Go to top

Lung Cancer

Title(s):
RTOG 1306. A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-Small Cell Lung Cancer (NSCLC)

Investigator(s):
Mitchel Fromm, MD

Contact Information:
McDowell Cancer Research at 330-344-6348


Go to top

Lung Cancer

Title(s):
CTSU A151216. Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

Investigator(s):
Esther Rehmus, MD

Contact Information:
McDowell Cancer Research at 330-344-6348


Go to top

Lung Cancer

Title(s):
CTSU A081105. Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)

Investigator(s):
Esther Rehmus, MD

Contact Information:
McDowell Cancer Research at 330-344-6348


Go to top

Lung Cancer

Title(s):
CTSU E4512. A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

Investigator(s):
Esther Rehmus, MD

Contact Information:
McDowell Cancer Research at 330-344-6348


Go to top

Lung Cancer

Title(s):
NRG-BR001. A Phase 1 Study of Stereotactic Body Radiotherapy (SBRT) for the Treatment of Multiple Metastases

Investigator(s):
Mitchel Fromm, MD

Contact Information:
McDowell Cancer Center at 330-344-6348


Go to top

Lung Cancer

Title(s):
SWOG 1403. A Randomized Phase II/III Trial of Afatinib Plus Cetuximab Versus Afatinib Alone in Treatment-Naive Patients with Advanced, EGFR Mutation Positive Non-Small Cell Lung Cancer (NSCLC) (BI 1200.124)

Investigator(s):
Esther Rehmus, MD

Contact Information:
McDowell Cancer Research at 330-344-6348


Go to top

Lung Cancer

Title(s):
NRG-CC003. Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer

Investigator(s):
Mitchel Fromm, MD

Contact Information:
McDowell Cancer Research at 330-344-6348


Go to top

Lymphoma

Title(s):
CTSU E1412. Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients with Newly Diagnosed Diffuse Large B Cell Lymphoma

Investigator(s):
Esther Rehmus, MD

Contact Information:
McDowell Cancer Research at 330-344-6348


Go to top

Lymphoma

Title(s):
16004. Case No. 5Z08 Clinical Trial Center for Hematologic Malignancies, The Leukemia & Lymphoma Society and Cleveland Clinic Taussig Cancer Center Partnership Tissue Acquisition

Investigator(s):
Esther Rehmus, MD

Contact Information:
McDowell Cancer Research at 330-344-6348


Go to top

Metastatic Cancer

Title(s):
NRG-BR001. A Phase 1 Study of Stereotactic Body Radiotherapy (SBRT) for the Treatment of Multiple Metastases

Investigator(s):
Mitchel Fromm, MD

Contact Information:
McDowell Cancer Research 330-344-6348


Go to top

Pancreas Cancer

Title(s):
RTOG 0848. A Phase III Trial Evaluating Both Erlotinib and Chemoradiation as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma

Investigator(s):
Mitchel Fromm, MD

Contact Information:
McDowell Cancer Research at 330-344-6348


Go to top

Prostate Cancer

Title(s):
RTOG 0924. Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial

Investigator(s):
Mitchel Fromm, MD

Contact Information:
McDowell Cancer Research at 330-344-6348


Go to top

Prostate Cancer

Title(s):
15027. A Pilot Study of Dexamethasone Therapy Prior to Rechallenge with Enzalutamide in Men with Metastatic Castration-Resistant Prostate Cancer Dex EXTends Enza Response (The DEXTER Trial)

Investigator(s):
Esther Rehmus, MD

Contact Information:
McDowell Cancer Research at 330-344-6348


Go to top



Cleveland Clinic Akron General • 1 Akron General Avenue • Akron, OH 44307 • 330.344.6000 • 1.800.221.4601    © 2016 Cleveland Clinic Akron General



This website is certified by Health On the Net Foundation. Click to verify.

  This site complies with the HONcode standard for trustworthy health information: verify here.